Tackling TKI resistance in AML: A commentary on “Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML.” by Yamatani et al.
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-05-01
|
| Series: | Translational Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523322000560 |
| _version_ | 1819022854207832064 |
|---|---|
| author | Özden Hatırnaz Ng Ahmet Emre Eşkazan |
| author_facet | Özden Hatırnaz Ng Ahmet Emre Eşkazan |
| author_sort | Özden Hatırnaz Ng |
| collection | DOAJ |
| first_indexed | 2024-12-21T04:29:36Z |
| format | Article |
| id | doaj.art-1f528354e1434084a674eb15577ef571 |
| institution | Directory Open Access Journal |
| issn | 1936-5233 |
| language | English |
| last_indexed | 2024-12-21T04:29:36Z |
| publishDate | 2022-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Translational Oncology |
| spelling | doaj.art-1f528354e1434084a674eb15577ef5712022-12-21T19:15:58ZengElsevierTranslational Oncology1936-52332022-05-0119101394Tackling TKI resistance in AML: A commentary on “Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML.” by Yamatani et al.Özden Hatırnaz Ng0Ahmet Emre Eşkazan1Department of Medical Biology, School of Medicine, Acıbadem University, Istanbul, TurkeyDepartment of Internal Medicine, Division of Hematology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Fatih, Istanbul, Turkey; Corresponding author.http://www.sciencedirect.com/science/article/pii/S1936523322000560Acute myeloid leukemiaAMLFLT3FLT3-ITD/D835BCL2A1Resistance |
| spellingShingle | Özden Hatırnaz Ng Ahmet Emre Eşkazan Tackling TKI resistance in AML: A commentary on “Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML.” by Yamatani et al. Translational Oncology Acute myeloid leukemia AML FLT3 FLT3-ITD/D835 BCL2A1 Resistance |
| title | Tackling TKI resistance in AML: A commentary on “Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML.” by Yamatani et al. |
| title_full | Tackling TKI resistance in AML: A commentary on “Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML.” by Yamatani et al. |
| title_fullStr | Tackling TKI resistance in AML: A commentary on “Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML.” by Yamatani et al. |
| title_full_unstemmed | Tackling TKI resistance in AML: A commentary on “Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML.” by Yamatani et al. |
| title_short | Tackling TKI resistance in AML: A commentary on “Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML.” by Yamatani et al. |
| title_sort | tackling tki resistance in aml a commentary on inhibition of bcl2a1 by stat5 inactivation overcomes resistance to targeted therapies of flt3 itd d835 mutant aml by yamatani et al |
| topic | Acute myeloid leukemia AML FLT3 FLT3-ITD/D835 BCL2A1 Resistance |
| url | http://www.sciencedirect.com/science/article/pii/S1936523322000560 |
| work_keys_str_mv | AT ozdenhatırnazng tacklingtkiresistanceinamlacommentaryoninhibitionofbcl2a1bystat5inactivationovercomesresistancetotargetedtherapiesofflt3itdd835mutantamlbyyamatanietal AT ahmetemreeskazan tacklingtkiresistanceinamlacommentaryoninhibitionofbcl2a1bystat5inactivationovercomesresistancetotargetedtherapiesofflt3itdd835mutantamlbyyamatanietal |